Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT

Key Points

• Dimensional Fund Advisors LP reduced its Sarepta Therapeutics position by 26.5%, selling 121,412 shares and retaining 336,736 shares worth approximately $7.3 million.
• Institutional investors own 86.68% of Sarepta, with Vanguard increasing its stake by 9.2% and several other firms establishing or expanding positions.
• Analyst sentiment is mixed: nine analysts rate the stock a Buy, five a Hold and six a Sell, producing a consensus Hold rating and an average price target of $25.06 versus the stock’s $17.18 opening price.

Dimensional Fund Advisors LP lessened its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 26.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 336,736 shares of the biotechnology company's stock after selling 121,412 shares during the quarter. Dimensional Fund Advisors LP owned 0.32% of Sarepta Therapeutics worth $7,323,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Sarepta Therapeutics by 9.2% in the fourth quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company's stock worth $254,167,000 after purchasing an additional 993,283 shares during the last quarter. M&T Bank Corp bought a new position in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $1,794,000. CWM LLC grew its stake in shares of Sarepta Therapeutics by 230.8% during the fourth quarter. CWM LLC now owns 240,536 shares of the biotechnology company's stock valued at $5,176,000 after buying an additional 167,831 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth approximately $1,935,000. Finally, Merit Financial Group LLC purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter worth approximately $820,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Wolfe Research upgraded Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a research note on Thursday, July 9th. HC Wainwright reissued a "buy" rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th. Weiss Ratings cut shares of Sarepta Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a report on Wednesday, August 5th. Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating on the stock in a research note on Thursday, July 9th. Finally, Wall Street Zen lowered shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday. Nine investment analysts have rated the stock with a Buy rating, five have given a Hold rating and six have given a Sell rating to the company. Based on data from MarketBeat, Sarepta Therapeutics has a consensus rating of "Hold" and an average price target of $25.06.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $17.18 on Tuesday. Sarepta Therapeutics, Inc. has a 1-year low of $14.68 and a 1-year high of $25.32. The business has a 50-day moving average price of $16.91 and a 200 day moving average price of $18.46. The company has a market capitalization of $1.81 billion, a P/E ratio of -5.92, a PEG ratio of 0.22 and a beta of 0.24. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source